Study of Outcomes of Smoking Cessation Interventions in Tuberculosis Patients using Urinary Cotinine Levels OC07-OC10
Dr. Deeptika Agarwal,
H. No. 109/5, Mandirwali Gali, Shakti Nagar, Rewari, Haryana, India.
Introduction: In a developing country like India, patients of pulmonary Tuberculosis (TB) form an important subset of individuals requiring smoking cessation counselling and pharmacotherapy. Smoking increases risk of Mycobacterium Tuberculosis (MTB) infection, the risk of progression from infection to disease and the risk of death from TB. Smoking cessation counselling and pharmacological therapy help in improving outcomes of TB treatment, reduce transmission of TB and improve the quality of life of TB patients.
Aim: To assess the effectiveness of smoking cessation counselling combined with bupropion in patients of pulmonary tuberculosis using urinary cotinine levels. The study was a prospective interventional study, carried out at Out Patient Department (OPD) and inpatient setting of a tertiary care respiratory centre in an urban setting between the period of July 2016 to June 2019.
Materials and Methods: Seventy-six pulmonary TB patients who were active tobacco smokers and fulfilled the inclusion criteria were recruited for the study. Subjects received smoking cessation counselling for one year along with tab bupropion for first three months. Effectiveness of the interventions was assessed by regular follow-up visits at one month, three months, six months and twelve months post-initiation of therapy. Data analysis was done by using SPSS version 17.0 and Microsoft Excel. Chi-square test was used and p-value <0.05 was considered significant.
Results: A total of 63 subjects were eligible for statistical analysis. Abstinence rates with bupropion and smoking cessation counselling at 12 months of follow-up were found to be 15.9%. Abstinence rates were found to be higher in patients with low nicotine dependence.
Conclusion: The study will provide data on smoking cessation with counselling and bupropion in Indian patients suffering from pulmonary TB.